International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 196-200
EVALUATION OF EARLY TOXICITY AND RESPONSE IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER TREATED WITH ACCELERATED CONCOMITANT BOOST RADIOTHERAPY
MUSTAFA İZMİRLİ1, FUAT YAMAN1, YAKUP BÜYÜKPOLAT1, ADNAN YÖNEY1, MUSTAFA ÜNSAL1
SSK Okmeydanı Eğitim ve Araştırma Hastanesi Radyasyon Onkolojisi Kliniği, İSTANBUL
Keywords: nsclc, radiotherapy, acute toxicity, treatment response
Poor results obtained with conventional radiotherapy in the treatment of non-small cell lung cancer have revived treatment with different fractionations. In our clinic concomitant boost radiotherapy was applied to 30 patients between June 2000 and December 2001 in two arms namely with Co-60 and linear accelerator. Therapy was completed after total 63 Gy dose (180 cGy for 35 fractions) administered within 5 weeks. After completion of the therapy 26 patients were evaluated. They were assesed with respect to acute side effects, dermal, esophageal and lung toxicities. Among patients treated with Co-60, grade 3-4 toxicity was not seen except one patient with grade 3 dermal toxicity. Only acute dermal reactions were statistically significant in patients treated with Co-60 in comparison with the group treated with linear accelerator (p=0.012). Complete and partial radiological response rates were determined to be 7.6% and 50% respectively. In conclusion, it was thought that therapy Schedule of accelerated concomitant boost radiotherapy is applicable with acceptable toxicities and improved response rates.
MUSTAFA İZMİRLİ1, FUAT YAMAN1, YAKUP BÜYÜKPOLAT1, ADNAN YÖNEY1, MUSTAFA ÜNSAL1
SSK Okmeydanı Eğitim ve Araştırma Hastanesi Radyasyon Onkolojisi Kliniği, İSTANBUL
Keywords: nsclc, radiotherapy, acute toxicity, treatment response
Poor results obtained with conventional radiotherapy in the treatment of non-small cell lung cancer have revived treatment with different fractionations. In our clinic concomitant boost radiotherapy was applied to 30 patients between June 2000 and December 2001 in two arms namely with Co-60 and linear accelerator. Therapy was completed after total 63 Gy dose (180 cGy for 35 fractions) administered within 5 weeks. After completion of the therapy 26 patients were evaluated. They were assesed with respect to acute side effects, dermal, esophageal and lung toxicities. Among patients treated with Co-60, grade 3-4 toxicity was not seen except one patient with grade 3 dermal toxicity. Only acute dermal reactions were statistically significant in patients treated with Co-60 in comparison with the group treated with linear accelerator (p=0.012). Complete and partial radiological response rates were determined to be 7.6% and 50% respectively. In conclusion, it was thought that therapy Schedule of accelerated concomitant boost radiotherapy is applicable with acceptable toxicities and improved response rates.